Reported about 14 hours ago
With 2025 just around the corner, JPMorgan has identified HA Sustainable Infrastructure Capital (HASI) and Xenon Pharmaceuticals (XENE) as their must-have stocks for the year. HASI focuses on financing the transition from fossil fuels to renewable energy, boasting a strong dividend and solid investment portfolio. Meanwhile, XENE is advancing its promising treatments for epilepsy and major depression, with pivotal clinical trial data expected in the coming year. Both stocks hold a 'Strong Buy' consensus rating, attracting attention from investors.
Source: YAHOO